NCT01005251 - Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI | Biotech Hunter

Enrollment

661

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions

Gastroesophageal Reflux DiseaseHeartburnRegurgitation

Interventions

DRUG

lesogaberan (AZD3355)

60 mg, oral, capsules, bid for 4 w

DRUG

lesogaberan (AZD3355)

120 mg, oral, capsules, bid for 4 w

DRUG

lesogaberan (AZD3355)

180 mg, oral, capsules, bid for 4 w

DRUG

lesogaberan (AZD3355)

240 mg, oral, capsules, bid for 4 w

DRUG

Placebo

oral,capsules, bid for 4 w

Trial Locations (1)

Research Site, Oklahoma City